Last reviewed · How we verify
NCT02897596: EARLY-HEP-C
Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients
Phase 3 trial testing Grazoprevir 100 mg/d 8 weeks in Hepatitis C in 62 participants. Status unknown.
28 April 2019
Quick facts
| Lead sponsor | Fundacion Clinic per a la Recerca Biomédica |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 62 |
| Start date | 28 April 2017 |
| Primary completion | 28 April 2019 |
| Estimated completion | 30 October 2019 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Grazoprevir 100 mg/d 8 weeks — full drug profile →
- Elbasvir 50 mg/d 8 weeks — full drug profile →
- Grazoprevir 100 mg/d 12 weeks — full drug profile →
- Elbasvir 50 mg/d 12 weeks — full drug profile →
Conditions studied
- Hepatitis C — all drugs for Hepatitis C →
- HIV — all drugs for HIV →
Sponsor
Fundacion Clinic per a la Recerca Biomédica
Who can join
18 and older, any sex, with Hepatitis C or HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate the efficacy of 12 or 8 weeks treatment with Grazoprevir/Elbasvir in Early Chronic Hepatitis C GT1,4 in HIV co-infected patients and evaluate the safety and tolerability of Grazoprevir + Elbasvir in HIV-HCV co-infected patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02897596
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatitis C
Currently open trials in the same condition.
- NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
- NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
- NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
- NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
- NCT05208697 — Tele-Harm Reduction · NA · active not recruiting
Other Fundacion Clinic per a la Recerca Biomédica trials
Trials by the same sponsor.
- NCT07454096 — Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study · Phase 4 · not yet recruiting
- NCT07412873 — Study on Sexual Health and Self-perceived Quality of Life (PROMs) in Patients Treated for Cervical Cancer · Phase 4 · not yet recruiting
- NCT07163403 — First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptid · Phase 1 · recruiting
- NCT07105384 — Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear · Phase 2 · active not recruiting
- NCT06896617 — Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02897596 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacion Clinic per a la Recerca Biomédica
- Last refreshed: 15 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02897596.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing